← Catalyst calendarINM biotech catalysts & pipeline
INMED PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
INM-089 — FDA meeting
2027
In the event that the Merger is not consummated, InMed's development priorities for INM-089, subject to financing transactions to fund operations, include generation of data supporting continued evaluation of therapeutic potential, completion of preclinical studies including dose-ranging assessment demonstrating dose proportionality and pharmacologically relevant concentration following dosing, drug substance and drug product process development to support IND-enabling studies, and planning for a pre-IND meeting with the FDA in early calendar 2027.
Source filingINM-901 — IND submission
2027
Furthermore, subject to regulatory feedback and financing transactions to fund completion of IND-enabling activities, InMed targets submission of an IND and initiation of a Phase 1 clinical trial in calendar 2027.
Source filingMT-002 — Clinical data readout
2027
These programs include MT-001, an anti-PACAP (pituitary adenylate cyclase-activating polypeptide) monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a potentially first-in-class anti-CGRP (calcitonin gene-related peptide) and anti-PACAP bispecific antibody with Phase 1 healthy volunteer data expected in 2027.
Source filingMT-002 — IND submission
1Q 2027
First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively
Source filingMT-001 — Clinical data readout
2028
These programs include MT-001, an anti-PACAP (pituitary adenylate cyclase-activating polypeptide) monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a potentially first-in-class anti-CGRP (calcitonin gene-related peptide) and anti-PACAP bispecific antibody with Phase 1 healthy volunteer data expected in 2027.
Source filingExplore the free biotech catalyst calendar
